Trial reportEuropean journal of nuclear medicine and molecular imaging2010
Clearance of the high intestinal (18)F-FDG uptake associated with metformin after stopping the drug.
Trial report in European journal of nuclear medicine and molecular imaging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 73 citations in OpenAlex.
- Trial
- 18F-FDG uptake in the colon is modulated by metformin but not associated with core body temperature and energy expenditure.PloS one · 2017Trial
- Impact of biguanide therapy on hepaticAnnals of nuclear medicine · 2026Article
- Organ-specific accuracy of [Japanese journal of radiology · 2024Article
- Focal incidental colorectal fluorodeoxyglucose uptake: Should it be spotlighted?World journal of clinical cases · 2024Article
- Unexpected focal fluorodeoxyglucose uptake in main organs; pass through or pass by?World journal of clinical cases · 2024Review
- The effect of additional acarbose on metformin-associated artificially highActa diabetologica · 2022Article
- Effect of metformin onThe British journal of radiology · 2022Review
- Metformin action in the gut-insight provided by [Diabetology international · 2022Article
- Interim [European journal of nuclear medicine and molecular imaging · 2021Article
- SNMMI Procedure Standard/EANM Practice Guideline on PediatricJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Discontinuation of metformin to prevent metformin-induced high colonic FDG uptake: is 48 h sufficient?Annals of nuclear medicine · 2020Article
- Toward Molecular Imaging of Intestinal Pathology.Inflammatory bowel diseases · 2020Review
- Glucose transporters in the small intestine in health and disease.Pflugers Archiv : European journal of physiology · 2020Review
- Association Between ColonicNuclear medicine and molecular imaging · 2020Article
- Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport.Scientific reports · 2019Article
- PET-CT reveals increased intestinal glucose uptake after gastric surgery.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2019Article
- Metformin and cancer: Technical and clinical implications for FDG-PET imaging.World journal of radiology · 2015Article
- Diffuse bowel uptake of 18F-FDG on PET/CT examination of a patient with diabetes treated with metformin.BMJ case reports · 2014Article
- 18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study.Bone marrow transplantation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study was done to determine whether interruption of metformin before (18)F-FDG PET/CT imaging could prevent the increased (18)F-FDG uptake in the intestine caused by this drug.
methodsIncluded in the study were 41 patients with known type 2 diabetes mellitus who were referred to our department for evaluation of various neoplastic diseases. Patients underwent two (18)F-FDG PET/CT scans, the first while they were on metformin and the second after they had stopped metformin. They stopped metformin and did not take any other oral antidiabetic medication starting 3 days before the second study and their blood glucose level was regulated with insulin when necessary to keep it within the range 5.55-8.33 mmol/l. FDG uptake was graded visually according to a four-point scale and semiquantitatively by recording the maximum standardized uptake value (SUVmax) in different bowel segments. A paired-samples t-test method was used to determine whether there was a significant difference between SUVmax measurements and visual analysis scores of the metabolic activity of the bowel in the PET/CT scans before and after stopping metformin.
resultsDiffuse and intense (18)F-FDG uptake was observed in bowel segments of patients, and the activity in the colon was significantly decreased both visually and semiquantitatively in PET/CT scans performed after patients stopped metformin (p<0.05). There was a statistically significant decrease in activity in the small intestine on visual analysis (p<0.05), but semiquantitative measurements did not show a significant decrease in the SUVmax values in the duodenum or jejunum (p>0.05).
conclusionMetformin causes an increase in (18)F-FDG uptake in the bowel and stopping metformin before PET/CT study significantly decreased this unwanted uptake, especially in the colon, facilitating the interpretation of images obtained from the abdomen and preventing the obliteration of lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.